Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: A target trial emulation study
Front. Immunol 2025;16:1673970 Doi: 10.3389/fimmu.2025.1673970
Bai et al. reported that JAKi therapy was associated with a reduced risk of incident uveitis compared with TNF inhibitors among patients with AS, PsO, or PsA. Authors conducted a large-scale, real world comparative study which evaluated the risk of incident uveitis among patients with psoriatic disease and AS treated with either TNFi or JAKi.
This is the first study that investigated the association between tsDMARDs, biologic agents and the risk of uveitis using large-scale real-world data. Findings support a potential therapeutic role for JAK inhibitors in mitigating ocular inflammatory risk in this population.
